Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.

• DOI: 10.11817/j.issn.1672-7347.2021.201009
• Publication Date: 2021-10-28
• Authors: Yuhan Zhang; Yaoshuai Zhang; Wenwen Niu; Xianming Ge; Xian Li; Fangtian Fan; Shanshan Li; Hao Liu
• Keywords: T790M; Gentamicin protection assay

Lung cancer is one of the most common malignant tumors in world, and its lethality ranks first among many tumors. For non-small cell lung (NSCLC) patients, due to high mortality rate, overall 5-year survival rate less than 15%. When NSCLC undergoes local invasion, only 20%, it even lower when distant metastasis occurs up 4%. Almonertinib an innovative drug independently researched developed by China with independent intellectual property rights. As epidermal growth factor receptor tyrosine kinase inhibitor, almonertinib mainly used for locally advanced or metastatic patients (EGFR) T790M mutation. This study aims investigate effects on proliferation, invasion migration cells vitro.